Dew drops, in which TB germs thrive, depend on factors like temperature and humidity.
Trials show that the standard six-month course for TB can be cut by two months for child patients.
A new three-drug combination is being tested on extensively drug-resistant TB cases in Tajikistan.
Dolutegravir, an anti-HIV drug that may be key to reducing the global incidence of TB, awaits large-scale clinical trials.
News
21/04/22
24/03/22
19/10/21
14/06/21
24/05/21
23/03/21
03/02/21
22/09/20
20/06/20
Our webfeeds enable you to embed the latest SciDev.Net stories into your website. Simply insert the following code into your web template to activate our latest news and analysis into your site.
<script type="text/javascript" src="https://www.scidev.net/asia-pacific/health/tb"></script>
> How to set up and customise your webfeed